Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
11.04
+0.04 (0.36%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Roivant Sciences Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Roivant Sciences stock have an average target of 17.5, with a low estimate of 12.5 and a high estimate of 22. The average target predicts an increase of 58.51% from the current stock price of 11.04.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Roivant Sciences stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 4 | 1 |
| Buy | 4 | 4 | 4 | 3 | 3 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 8 | 8 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +63.04% | Apr 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +63.04% | Feb 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +63.04% | Nov 13, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +63.04% | Sep 19, 2024 |
Financial Forecast
Revenue This Year
96.24M
from 124.80M
Decreased by -22.88%
Revenue Next Year
28.63M
from 96.24M
Decreased by -70.25%
EPS This Year
-0.36
from 5.23
EPS Next Year
-1.28
from -0.36
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 156.0M | 63.0M | 163.8M | |||
| Avg | 96.2M | 28.6M | 69.2M | |||
| Low | 73.1M | 7.0M | 23.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 25.0% | -34.5% | 472.1% | |||
| Avg | -22.9% | -70.2% | 141.5% | |||
| Low | -41.4% | -92.8% | -17.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.13 | -1.08 | -1.22 | |||
| Avg | -0.36 | -1.28 | -1.46 | |||
| Low | -0.66 | -1.43 | -1.83 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.